Cultivation |
Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin. |
Miller AA, Traczewski MM, Huband MD, Bradford PA, Mueller JP |
J Clin Microbiol |
10.1128/JCM.00567-19 |
2019 |
* |
Pathogenicity |
Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide. |
Hackel MA, Karlowsky JA, Dressel D, Sahm DF |
J Clin Microbiol |
10.1128/JCM.00972-17 |
2017 |
* |
Pathogenicity |
Implementation of the new VIRTUO blood culture system: evaluation and comparison to the 3D system using simulated blood cultures. |
Miller N, Brassinne L, Allemeersch D |
Acta Clin Belg |
10.1080/17843286.2017.1331618 |
2017 |
* |
Metabolism |
[Mouse macrophage-derived chemokine as an adjuvant enhances the protective effect of P6 protein vaccine of nontypeable Haemophilus influenzae]. |
Han X, Wang C, Qiao H, Zhang Y, Chang Y, Zhang Y |
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi |
|
2014 |
* |
Pathogenicity |
Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. |
Ross JE, Scangarella-Oman NE, Flamm RK, Jones RN |
J Clin Microbiol |
10.1128/JCM.00656-14 |
2014 |
* |
Pathogenicity |
Activity of the antiseptic polyhexanide against gram-negative bacteria. |
Fabry WH, Kock HJ, Vahlensieck W |
Microb Drug Resist |
10.1089/mdr.2013.0113 |
2013 |
* |
Pathogenicity |
Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial. |
Ross JE, Scangarella-Oman N, Jones RN |
Diagn Microbiol Infect Dis |
10.1016/j.diagmicrobio.2013.01.007 |
2013 |
* |
Pathogenicity |
Antimicrobial susceptibility testing of Streptococcus pneumoniae and Haemophilus influenzae --internal quality control as a quality tool on a national level. |
Karpanoja P, Nissinen A, Huovinen P, Sarkkinen H |
APMIS |
10.1111/apm.12021 |
2012 |
* |
Pathogenicity |
Antimicrobial and antioxidant properties of Betula aetnensis Rafin. (Betulaceae) leaves extract. |
Acquaviva R, Menichini F, Ragusa S, Genovese C, Amodeo A, Tundis R, Loizzo MR, Iauk L |
Nat Prod Res |
10.1080/14786419.2012.695364 |
2012 |
* |
Pathogenicity |
Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. |
Ross JE, Scangarella-Oman NE, Miller LA, Sader HS, Jones RN |
J Clin Microbiol |
10.1128/JCM.01213-11 |
2011 |
* |
Pathogenicity |
Determination of disk diffusion and MIC quality control guidelines for JNJ-Q2, a novel quinolone. |
Ross JE, Liverman LC, Jones RN |
J Clin Microbiol |
10.1128/JCM.00636-11 |
2011 |
* |
Enzymology |
[Cloning Hap gene from non-typeable Haemophilus influenzae and expression of Hap protein in prokaryotic cell]. |
Li W, Kuang Y, Yao F, Yang Y, Chen C, Jiang Z, Li M |
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi |
|
2009 |
* |
Enzymology |
[Species-identification and antimicrobial susceptibility tests by the fully automated RAISUS using an early-harvested cell suspension]. |
Nakasone I, Kisanuki K, Higa M, Kinjo T, Yamane N |
Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi |
|
2006 |
* |
Cultivation |
Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. |
Brown SD, Traczewski MM |
J Clin Microbiol |
10.1128/JCM.02351-06 |
2007 |
* |
Pathogenicity |
Impact of carbon dioxide on the susceptibility of key respiratory tract pathogens to telithromycin and azithromycin. |
Bouchillon SK, Johnson JL, Hoban DJ, Stevens TM, Johnson BM |
J Antimicrob Chemother |
10.1093/jac/dki156 |
2005 |
* |
Pathogenicity |
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor. |
Anderegg TR, Jones RN |
Diagn Microbiol Infect Dis |
10.1016/S0732-8893(03)00162-7 |
2004 |
* |
Pathogenicity |
Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae. |
Anderegg TR, Biedenbach DJ, Jones RN |
Diagn Microbiol Infect Dis |
10.1016/s0732-8893(03)00039-7 |
2003 |
* |
Pathogenicity |
Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756). |
Hayashi K, Takahata M, Kawamura Y, Todo Y |
Arzneimittelforschung |
10.1055/s-0031-1299988 |
2002 |
* |
Phylogeny |
Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. |
Dabernat H, Delmas C, Seguy M, Pelissier R, Faucon G, Bennamani S, Pasquier C |
Antimicrob Agents Chemother |
10.1128/AAC.46.7.2208-2218.2002 |
2002 |
* |
Enzymology |
Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae. |
Bolmstrom A, Karlsson A |
Diagn Microbiol Infect Dis |
10.1016/s0732-8893(01)00338-8 |
2002 |
* |
Pathogenicity |
Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains. |
Biedenbach DJ, Jones RN |
Diagn Microbiol Infect Dis |
10.1016/s0732-8893(01)00294-2 |
2001 |
* |
Pathogenicity |
Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001). |
Jones RN, Biedenbach DJ |
Diagn Microbiol Infect Dis |
10.1016/s0732-8893(01)00236-x |
2001 |
* |
Cultivation |
Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media. |
Marshall SA, Kugler KC, Jones RN |
Int J Antimicrob Agents |
10.1016/s0924-8579(00)00180-1 |
2000 |
* |
Phylogeny |
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. |
Jones RN, Biedenbach DJ, Erwin ME, Beach ML, Pfaller MA |
J Clin Microbiol |
10.1128/JCM.37.6.1999-2002.1999 |
1999 |
* |
Pathogenicity |
Escherichia coli ATCC 35218 as a quality control isolate for susceptibility testing of Haemophilus influenzae with haemophilus test medium. |
Butler DL, Jakielaszek CJ, Miller LA, Poupard JA |
Antimicrob Agents Chemother |
10.1128/AAC.43.2.283 |
1999 |
* |
Pathogenicity |
Microbiologic effect of bovine cerebrospinal fluid and azithromycin against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. |
Destache CJ, Pakiz CB, Kersting K |
Pharmacotherapy |
|
1997 |
* |
Pathogenicity |
Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group. |
Fuchs PC, Barry AL, Brown SD |
J Clin Microbiol |
10.1128/jcm.35.1.125-131.1997 |
1997 |
* |
Pathogenicity |
Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628). |
Sewell DL, Barry AL, Allen SD, Fuchs PC, Jorgensen JH, Tenover F |
Diagn Microbiol Infect Dis |
10.1016/0732-8893(95)00021-2 |
1995 |
* |
Pathogenicity |
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group. |
Bale MJ, Jones RN, Erwin ME |
Diagn Microbiol Infect Dis |
10.1016/0732-8893(94)90054-x |
1994 |
* |
Pathogenicity |
Agar disk diffusion (Bauer-Kirby) tests with various fastidious and nonfastidious reference (ATCC) strains: comparison of several agar media. |
Traub WH, Leonhard B |
Chemotherapy |
10.1159/000239296 |
1994 |
* |
Pathogenicity |
Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters. |
Barry AL, Fuchs PC, Allen SD, Jorgensen JH, Tenover FC, Murray PR, Hardy DJ, Baker CN |
J Clin Microbiol |
10.1128/jcm.31.9.2375-2380.1993 |
1993 |
* |
Pathogenicity |
Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests. |
Barry AL, Fuchs PC, Jorgensen JH, Tenover FC, Allen SD, Hardy DJ, McLaughlin JC |
J Clin Microbiol |
10.1128/jcm.31.3.751-753.1993 |
1993 |
* |
Pathogenicity |
Interpretive criteria and quality control parameters for testing susceptibility of Haemophilus influenzae to enoxacin, ofloxacin, and temafloxacin. |
Barry AL, Jorgensen JH, Hardy DJ, Allen SD, Baker CN, Fuchs PC, McLaughlin JC |
J Clin Microbiol |
10.1128/jcm.30.11.3013-3015.1992 |
1992 |
* |
Cultivation |
Performance of Haemophilus Test Media prepared with 12 different lots of Mueller-Hinton agar from four manufacturers. |
Barry AL, Packer RR |
J Clin Microbiol |
10.1128/jcm.30.5.1145-1147.1992 |
1992 |
* |
Pathogenicity |
Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin. |
Bale MJ, Jones RN, Erwin ME, Koontz FP, Gerlach EH, Murray PR, Washington JA |
J Clin Microbiol |
10.1128/jcm.30.3.744-745.1992 |
1992 |
* |
Pathogenicity |
Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium. |
Pfaller MA, Jones RN, Washington JA, Koontz FP, Gerlach EH, Erwin ME |
Diagn Microbiol Infect Dis |
10.1016/0732-8893(92)90039-v |
1992 |
* |
Pathogenicity |
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. |
Bale MJ, Jones RN, Erwin ME, Koontz FP, Gerlach EH, Murray PR, Washington JA |
J Clin Microbiol |
10.1128/jcm.30.1.225-226.1992 |
1992 |
* |
Cultivation |
Quality control limits for disk diffusion and broth microdilution susceptibility tests with Haemophilus test medium. |
Doern GV, Gerlach EH, Jorgensen JH, Murray PR, Thornsberry C, Washington JA Jr |
Diagn Microbiol Infect Dis |
10.1016/0732-8893(91)90004-y |
1991 |
* |
|
Endophytic Fungi from Alstonia boonei De Wild and Greenwayodendron suaveolens (Engl. and Diels) Verdc. subsp. Suaveolens Possess Inhibitory Activity against Pneumonia Causing Bacteria. |
Demeni PCE, Betote PHD, Kom CW, Tchamgoue EN, Ndedi Moni EDF, Foumane Maniepi JS, Agbor GA, Nyegue MA |
Evid Based Complement Alternat Med |
10.1155/2021/9966323 |
2021 |
* |
|
Antibacterial oral sprays from kaffir lime (Citrus hystrix DC.) fruit peel oil and leaf oil and their activities against respiratory tract pathogens. |
Srifuengfung S, Bunyapraphatsara N, Satitpatipan V, Tribuddharat C, Junyaprasert VB, Tungrugsasut W, Srisukh V |
J Tradit Complement Med |
10.1016/j.jtcme.2019.09.003 |
2019 |
* |
|
Antibacterial, Antioxidant, and Antiproliferative Activities of Corymbia citriodora and the Essential Oils of Eight Eucalyptus Species. |
Miguel MG, Gago C, Antunes MD, Lagoas S, Faleiro ML, Megias C, Cortes-Giraldo I, Vioque J, Figueiredo AC |
Medicines (Basel) |
10.3390/medicines5030061 |
2018 |
* |